Evidence map›Paper›PMID 24274400›Full record

ArticleJournal of medicinal chemistry2013

Scaffold ranking and positional scanning utilized in the discovery of nAChR-selective compounds suitable for optimization studies.

Jinhua Wu, Yaohong Zhang, Laura E Maida, Radleigh G Santos, Gregory S Welmaker, Travis M LaVoi, Adel Nefzi, Yongping Yu, Richard A Houghten, Lawrence Toll and 1 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Identification and characterization of an atypical Gαs-biased βProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Identification of Protein Palmitoylation Inhibitors from a Scaffold Ranking Library.Combinatorial chemistry & high throughput screening · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jinhua WuTorrey Pines Institute for Molecular Studies , 11350 SW Village Parkway, Port St. Lucie, Florida 34987, United States.
Yaohong Zhang
Laura E Maida
Radleigh G Santos
Gregory S Welmaker
Travis M LaVoi
Adel Nefzi
Yongping Yu
Richard A Houghten
Lawrence Toll
Marc A Giulianotti

Funding

High throughput in vivo screening: translational generation of novel analgesicsR01DA031370 · NIDA · TORREY PINES INST FOR MOLECULAR STUDIES · PI HOUGHTEN, RICHARD ALLEN · 2011 to 2015
$2.2M
Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse MedicationsR41AA025298 · NIAAA · ASSUAGE PHARMACEUTICALS, INC. · PI TOLL, LAWRENCE R · 2016 to 2016
$225k
NIAAA NIH HHS R41 AA025298NIDA NIH HHS R01 DA031370NIDA NIH HHS R01-DA031370
6 · The paper itself

Abstract

Nicotine binds to nicotinic acetylcholine receptors (nAChR), which can exist as many different subtypes. The α4β2 nAChR is the most prevalent subtype in the brain and possesses the most evidence linking it to nicotine seeking behavior. Herein we report the use of mixture based combinatorial libraries for the rapid discovery of a series of α4β2 nAChR selective compounds. Further chemistry optimization provided compound 301, which was characterized as a selective α4β2 nAChR antagonist. This compound displayed no agonist activity but blocked nicotine-induced depolarization of HEK cells with an IC50 of approximately 430 nM. 301 demonstrated nearly 500-fold selectivity for binding and 40-fold functional selectivity for α4β2 over α3β4 nAChR. In total over 5 million compounds were assessed through the use of just 170 samples in order to identify a series of structural analogues suitable for future optimization toward the goal of developing clinically relevant smoking cessation medications.

Indexed as

Drug DiscoveryCells, CulturedDose-Response Relationship, DrugHumansMolecular StructureReceptors, NicotinicSmall Molecule LibrariesStructure-Activity RelationshipReceptors, NicotinicSmall Molecule Libraries

Identifiers

PMID24274400
PMCPMC4106133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.